Search

Displaying all 6 results
DrugBest match

Pralsetinib

go.drugbank.com/drugs/DB15822
ApprovedInvestigational

Pralsetinib, similar to the previously approved selpercatinib, is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. Althou...

  1. Indication

    Advanced RET-fusion Non Small Cell Lung Cancer

    go.drugbank.com/conditions/DBCOND0144083
    Drugs: Pralsetinib
  2. Indication

    Advanced RET-fusion thyroid cancer

    go.drugbank.com/conditions/DBCOND0129292
    Drugs: Pralsetinib · Selpercatinib
  3. Indication

    Metastatic RET-fusion Non Small Cell Lung Cancer

    go.drugbank.com/conditions/DBCOND0129285
    Drugs: Pralsetinib · Selpercatinib
  4. Indication

    Metastatic RET-fusion thyroid cancer

    go.drugbank.com/conditions/DBCOND0129294
    Drugs: Pralsetinib · Selpercatinib
  5. Drug

    Selpercatinib

    go.drugbank.com/drugs/DB15685
    ApprovedInvestigational

    Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.